Bay-38-4766. Anti-cytomegalovirus drug

Drugs of the Future

Volumn 24, Issue 12, 1999, Pages 1297-1300

  Sorbera, L A ^a   Leeson, P A ^a   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ADEFOVIR; ANTIVIRUS AGENT; BAY 43 9695; BENZIMIDAVIR; CIDOFOVIR; FOMIVIRSEN; FOSCARNET SODIUM; GANCICLOVIR; LOBUCAVIR; N [4 [5 (DIMETHYLAMINO) 1 NAPHTHYLSULFONAMIDO]PHENYL] 3 HYDROXY 2,2 DIMETHYLPROPIONAMIDE; PENCICLOVIR; RPR 111423; RPR 11143; SYNADENOL; SYNGUANOL; TOMEGLOVIR; UNCLASSIFIED DRUG; VALGANCICLOVIR;

ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CYTOMEGALOVIRUS; CYTOTOXICITY; DRUG ABSORPTION; DRUG METABOLISM; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; NONHUMAN; PLASMA CLEARANCE;

EID: 0033375734     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1999.024.12.561698     Document Type: Article

References (18)

1. Bender, W., Reefschlaeger, J., Eckenberg, P., Goldmann, S., Haerter, M., Hallenberger, S., Trappe, J., Weber, O. (Bayer AG). Novel naphthyl-substd. and anilide-substd. sulfonamides. WO 9937609.
2. Eckenberg, P., Reefschlaeger, J., Bender, W., Goldmann, S., Haerter, M., Hallenberger, S., Trappe, J., Weber, O. Structure-activity relationships of BAY 38-4766 - A novel nonnucleosidic inhibitor of human cytomegalovirus replication. 39th Intersci Conf Antimicrob Agents Chemother (Sept 26-29, San Francisco) 1999, Abst F940.
3. Whitcup, S.M., Fortin, E., Lindblad, A.S. et al. Discontinuation of anticytomegalovirus therapy in patients with HIV infection and cytomegalovirus retinitis. JAMA - J Am Med Assoc 1999, 282: 1633-7.
4. Reefschlaeger, J., Bender, W., Eckenberg, P., Goldmann, S., Haerter, M., Hallenberger, S., Paessens, A., Trappe, J., Weber, O. Antiviral activity and selectivity of BAY 38-4766 - A novel nonnucleosidic inhibitor of human cytomegalovirus replication. 39th Intersci Conf Antimicrob Agents Chemother (Sept 26-29, San Francisco) 1999, Abst F942.
5. Hallenberger, S., Trappe, J., Buerger, I., Bender, W., Eckenberg, P., Goldmann, S., Haerter, M., Reefschlaeger, J., Weber, O. Mechanism of antiviral action of BAY 38-4766 - A novel nonnucleosidic inhibitor of human cytomegalovirus replication. 39th Intersci Conf Antimicrob Agents Chemother (Sept 26-29, San Francisco) 1999, Abst F941.
6. Kern, A., Blombach, M. In vivo metabolism in rat and dog of BAY 38-4766 - A novel nonnucleosidic inhibitor of human cytomegalovirus replication. 39th Intersci Conf Antimicrob Agents Chemother (Sept 26-29, San Francisco) 1999, Abst F943.
7. Nagelschmitz, J., Möller, J.G., Stass, H.H., Wandel, C., Kuhlmann, J. Safety, tolerability, and pharmacokinetics of single oral doses of BAY 38-4766 - A novel nonnucleosidic inhibitor of human cytomegalovirus (HCMV) replication in healthy male subjects. 39th Intersci Conf Antimicrob Agents Chemother (Sept 26-29, San Francisco) 1999, Abst F945.
8. Witt-Laido, A., Beckermann, B., Schwarz, T., Steinke, W., Daehler, H., Henninger, K., Buehner, K. Pharmacokinetics in rat and dog of BAY 38-4766 - A novel nonnucleosidic inhibitor of human cytomegalovirus replication. 39th Intersci Conf Antimicrob Agents Chemother (Sept 26-29, San Francisco) 1999, Abst F944.
9. Bayer's CMV product advances to phase II. DailyDrugNews.com (Daily Essentials) December 2, 1999.
10. Iwayama, S., Ono, N., Ohmura, Y. et al. Antiherpesvirus activities of (1'S,2'R)-9-[[1',2'-bis(hydroxymethyl)cycloprop-1'-yl]methyl]guanine (A-5021) in cell culture. Antimicrob Agents Chemother 1998, 42: 1666-70.
11. Starrett, J.E. Jr., Tortolani, D.R., Hitchcock, M.J., Martin, J.C., Mansuri, M.M. Synthesis and in vitro evaluation of a phosphonate prodrug: bis(pivaloyloxymethyl) 9-(2-phosphonylmethoxyethyl)adenine. Antivir Res 1992, 19: 267-73.
12. Braitman, A., Swerdel, M.R., Olsen, S.J., Tuomari, A.V., Lynch, J.S., Blue, B., Michalik, T., Field, A.K., Bonner, D.P., Clark, J.M. Evaluation of SQ 34,514: Pharmacokinetics and efficacy in experimental herpesvirus infections in mice. Antimicrob Agents Chemother 1991, 35: 1464-8.
13. Bhattacharya, B.K., Ojwang, J.O., Rando, R.F., Huffman, J.H., Revankar, G.R. Synthesis and anti-DNA viral activities in vitro of certain 2,4-disubstituted-7-(2-deoxy-2-fluoro-beta-D-ara-binofuranosyl)pyrrolo[2,3-d] pyrimidine nucleosides. J Med Chem 1995, 38: 3957-66.
14. Benzaria, S., Pelicano, H., Johnson, R., Maury, G., Imbach, J.L., Aubertin, A.M., Obert, G., Gosselin, G. Synthesis, in vitro antiviral evaluation, and stability studies of bis(S-acyl-2-thioethyl) ester derivatives of 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA) as potential PMEA prodrugs with improved oral bioavailability. J Med Chem 1996, 39: 4958-65.
15. Snoeck, R., Andrei, G., Nemecek, C., De Clercq, E., Roy, C. In vitro inhibition of HCMV replication by the tetrahydroindolizine RPR111423. Antivir Res 1999, 41(2): Abst 12.
16. Azad, R.F., Driver, V.B., Tanaka, K., Crooke, R.M., Anderson, K.P. Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region. Antimicrob Agents Chemother 1993, 37: 1945-54.
17. Rybak, R.J., Zemlicka, J., Qiu, Y.L., Hartline, C.B., Kern, E.R. Effective treatment of murine cytomegalovirus infections with methylenecyclopropane analogues of nucleosides. Antivir Res 1999, 43: 175-88.
18. Tutonda, M.G., Buckheit, R.W. Jr., Agrawal, V.K., Broom, A.D. Antiviral oligo- and polyribonucleotides containing selected triazolo[2,3-a]purines. J Med Chem 1998, 41: 4958-64.